Oxazolinyl-isoflavans and -3(2H)-isoflavenes, substituted or not with a chlorine atom, were synthesized in order to compare their anti-rhinovirus activity with that of previously studied analogous compounds.
Introduction
Currently, particular attention is being given to the development of agents effective in the prophylaxis or therapy of the common cold. 4',6-Dichloroflavan (BW683C) is a highly potent inhibitor of rhinovirus (HRV) replication in vitro, with an IC so value of 0.007 f.LM against the serotype 1B of HRV (Bauer et al., 1981) . Halo-, cyano-, and arnidino-ftavans, isoflavans, and 3(2H)-isoflavenes, previously synthesized and tested by us, have been found to inhibit not only HRV 1B replication (Burali et al., 1987; Conti et al., 1988; by base-catalized cyclization of 2-(p-carbethoxyphenacyloxy)benzyl triphenylphosphonium bromide, obtained by reaction of 2-hydroxybenzylalcohol with ethyl 4-bromoacetylbenzoate and treatment with triphenylphosphine hydrobromide (Scheme II).
Cell morphology and growth in the presence of compounds
The first set of experiments was carried out in order to determine the maximum non-toxic concentration of the compounds for HeLa cells. Two-fold serial dilutions of compounds were incubated at 37°C with cell monolayers and, after 3 days, cell morphology and Viability were examined. Table 1 reports the highest concentrations of each drug which had no effect on the above mentioned parameters in 100% of the cells. To further testthe toxicity of compounds for cultured cells, the inhibition of cell proliferation was measured. Table 1 shows that HeLa cells, seeded at low concentration, grow at the control rate in the presence of doses of drugs from 1 to 32 fold lower than that which produced CPE. Inhibition of cell growth, manifested by a 50% reduction in cell number as compared to the controls (TC so ), occurred at concentrations up to 32 times higher than the maximum non toxic dose for cell growth.
Anilvifaleffectofcompounds
The new oxazolines 'Y, VI, XI, XII, XVII, XVIII), esters (IX, X, XV, XVI), and acids (XIII, XIV, XIX, XX) have been tested for their in vitro antiviral potential against HRV 1B infection of HeLa cell cultures. BW683C was included as a control. The HRVserotype 1B was selected because it is extremely sensitive to BW683C in vitro (Bauer et al., 1981) and therefore it allows a comparison with BW683C and the HeLa cells were grown for 3d at 37"C in the presence or absence of serial two-fold dilutions of compounds starting from the highest soluble dose. Cytotoxicity was evaluated by microscope examination of monolayers and by counting the cell number in drug-treated and untreated cultures. The TC so was the concentration of compound reducing the cell proliferation by 50% of the untreated control and was calculated by plotting the per cent of cell number in drug-exposed cultures in function of drug concentration. For compounds where> is indicated, the maximum non-toxic concentration was found to be higher than the saturation concentration in cell culture medium. b. The MIC 5 0 value was the concentration of the drug reducing viral CPE by 50% and was calculated by plotting the per cent of reduction of CPE versus the logarithm of the drug concentration. c. The IC 5 0 value was the concentration of the drug reducing the plaque number by 50% and was calculated by plotting the per cent of plaque reduction versus the logarithm of the drug concentration. d. The TC 5 0 value was found to be higher than the saturation concentration in cell culture medium.
compounds previously synthesized and tested by us (Burali et a/., 1987; Conti et a/., 1990; .
The inhibitory effect of the flavanoids on HRV 1B replication was monitored by the inhibition of Virus-induced cytopathic effect (CPE) and by reduction of plaque formation in HeLa cells. The 50% effective concentrations for effect on CPE (MIC 50) and on plaque formation (IC 50) are shown in Table  1 . These values have been calculated by plotting the per cent of reduction of viral CPE or plaque number against the logarithm of the compound dose, to yield a doseresponse line from which the 50% inhibitory dose could be calculated. Figure 2 shows the dose-dependent reduction of plaque number, produced by the incorporation of varying amounts of compounds into the culture medium.
The MIC 50s ranged from 4.70f.LM to more than 200f.LM while the IC 50 values were comprised between 0.11 f.LM and 5.60 f.LM. The difference in the MIC 50 and IC 50 values are the consequence of the input virus concentrations.
In the conditions of the assay, the MIC 50 and the IC 50 of BW683C resulted 0.32 f.LM and 0.038 f.LM, respectively.
Beside an effect on plaque number, some compounds tested (XI,XII, XIII, XIV, XVIII) produced a dose-dependent reduction (up to 80%) in viral plaque size, suggesting a slowing down in the kinetic of viral replication. In some cases (VI, IX, XVI, XVII, XIX, XX) the inhibitory effect was observed only at the highest dose allowing plaques to develop. Compounds V, X, XV did not alter median viral plaque size.
The therapeutic indexes, calculated by dividing the 50% cell proliferation inhibitory dose (TC 50) by the IC 5o, were markedly different (Table 1 ). In fact, the compounds were not toxic to the cells at concentrations that were from 2-to 400-fold in excess of those inhibiting virus replication.
Discussion
The new flavanoids exerted a significant inhibitory effect on HRV 1B infection in vitro, as demonstrated by both inhibition of virus-induced CPE and plaque number ( Fig. 2 and Table 1 ). The activity of the compounds could be due to a direct inactivation of virus infectivity or to an interference with HRV 1B replication in HeLa cells since the drugs were added to cell cultures together with virus inoculum and maintained until the end of the incubation period.
In plaque reduction assay, the compounds showed an activity comparable with that of the isoflavans and isoflavenes studied previously (Burali et a/., 1987; Conti et sl., 1990a) . Moreover, most of the new oxazolines were as effective as the related WINs, which showed IC ranging 
Log of compound concentration (11M) from 0.1 to 1.9fLM against HRV 1B (Diana et al., 1989) . None of the new flavanoids appeared more active than 4' ,6-dicyanoflavan (IC 50 0.023 fLM) (Conti et al., 1990a) , 4'-chloro,6-cyanoflavan (IC 50 0.0085 fLM) , and the reference compound BW683C (IC 50 0.038 fLM, in the conditions of the assay). Compounds were not inhibitory to host cell proliferation in vitro at doses ranging from 3.12 to 100 fLM. Based on the ratio between TC 50 and IC 50 it is estimated that the in vitro therapeutic indices may range from about 2 to 400.
As regards the position of the oxazolinyl residue on the isoflavan skeleton, it must be noted that the preference between the 6-or the 4'-position for the activity is reversed in respect to the flavans. In fact the IC 5 0 values of 4'-oxazolinylflavan and 6-oxazolinylflavan were found to be 0.56 and 4.01 fLM, respectively , while in the two new couples of isoflavenes (y and XI) and isoflavans (yl and XII) the 6-oxazolinyl derivatives appeared more active than the 4'-oxazolinyl compounds.
The positive influence of a chloro substituent on the activity of flavanoids has been noted previously (Bauer et al., 1981; Burali et al., 1987; Conti et al., 1990a) . Unfortunately, the enhanced anti-HRV 1B activity of the new chloro flavanoids was combined with the reduction of therapeutic index. We had unexpected results from the assay on the compounds bearing a free or esterified carboxylic group instead of the oxazoline ring. While the acids intermediates in the WIN synthesis exhibited no antiviral activity (Diana et al., 1985) , in the case of flavanoids all the acids and esters showed good IC 50 • values. In the isoflavene series, the acids were found to be more potent inhibitors than the corresponding esters, while the compounds bearing the oxazolinyl group were less active. Results in the isoflavan series are more variable, probably due to their less rigid structure permitting different conformations which lead to various possible space collocations of the acid group.
The acid XIX showed the lowest IC 50 value among all the isoflavans and isoflavenes tested until now (Burali et al., 1987 ; Conti et et., 1990a) , while its effect on the development of viral CPE and its therapeutic index result was moderate.
Taking into account the IC so , the MIC so , and the therapeutic index, 6-oxazolinylisoflavan (VI) seems to be a good candidate for further investigations. Tests against different rhinovirus serotypes and other picornaviruses are necessary to evaluate the effective interest of this new compound.
Materials and Experimental procedures: Chemistry
Melting points were determined in open glass capillaries on a BOchi SMP-20 apparatus (BOchi, Flawil, Switzerland) and are uncorrected. IR spectra were recorded on a Perkin-Elmer 1310 instrument Perkin-Elmer, Emeryville, CA, USA; NMR spectra on a Varian EM-390 90 MHz instrument Varian, Palo Alto, USA, using TMS as internal standard. The elemental analyses were within ± 0.4% of theoretical values. 6-Cyano-3(2H)-isoflavene (I) and 6-cyanoisoflavan (II)were previously described by us (Conti et el., 1990) .[(2-Hydroxyphenyl)methyl]triphenylphosphonium bromide and [(2-hydroxy-5-chlorophenyl)methyl]triphenylphosphonium bromide were prepared as in reference (Hercouet and Le Corre, 1979) . Ethyl 4-bromoacetylbenzoate was mentioned in patents (Phillips and Williamson, 1982; Allen, 1986, 1988; ; we synthesized it by esterification of acetylbenzoic acid, commercially available, and radicalic brornination.
Synthesis of oxazolines Vand VI
A solution of the cyanocompound I or II (0.01 mol) in a mixture of absolute ethanol (1 00 ml) and dry ethyl ether (100ml) was saturated with hydrochloric acid and left at room temperature. The reaction was followed by TLC until it was complete (average time 14days). Removal of the solvent under reduced pressure gave a solid residue that was triturated with ethyl ether and filtered. The crude iminoether was solubilized in dichloromethane (300ml) and dry triethylamine (0.04mol) was added. After stirring for 1h, the solution was washed with water and dried over Na2S04. The solvent was removed leaving a solid residue to which ethanolamine (0.04 mol) was added. The mixture was then heated to 120°C while stirring. At this point gas evolution (NH 3 ) was observed. After 1.5 h the melted mixture was cooled and the excess of ethanolamine was evaporated under reduced pressure. The residue was purified by column chromatography eluting with ethyl acetate and crystallized (Tables 2 and 3) . 
EthyI4-(2'-Hydroxymethylphenoxy)-acetylbenzoate (VII)
To a solution of 2-hydroxybenzylalcohol (0.01 mol) and ethyl 4-bromoacetylbenzoate (0.01 mol) in dry acetone (25 ml), anhydrous potassium carbonate (0.011 mol) was added. The mixture was heated at 80°C for 3h while stirring. After cooling, the suspension was filtered and the filtrate evaporated. The product was purified by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether (1 : 3 
[(2-Phenacyloxy-5-bromophenyl)methyljtriphenylphosph onium bromide (VIII)
To a solution of compound VII (0.01 mol) in acetonitrile (20ml), triphenylphosphine hydrobromide (0.01 mol) was added. The mixture was heated at 90°C for 2 h while stirring. After cooling, the crystalline precipitate was filtered and washed with ether. More product could be obtained by concentration of mother liquor. Mp 211-215°C. Yield 86%.IR (KBr): 1690,1710cm-1.
Synthesis of ethyl 4-{3-[1(2H)-benzopyranylj}-benzoate (IX) from [(2-phenacyloxy-5-bromophenyljmethylj triphenylphosphonium bromide (VIII)
The crude triphenylphosphonium salt VIII (0.01 mol) was suspended in absolute ethanol (25 ml) and a solution of sodium (0.01 mol) in absolute ethanol (12 ml) was added dropwise at room temperature, while stirring. After 12 h, water was added to the suspension in such amounts so as to have an ethanol-water mixture (3: 2). The crude isoflavene IX was filtered, washed with water and crystallized ( Table 2) .
Synthesis of 3(2H)-isoflavenes IX and XV from [(2hydroxyphenyljmethyljtriphenylphosphonium bromides
To a suspension of [(2-hydroxyphenyl)methyl]triphenylphosphonium bromide or [(2-hydroxy-5-chlorophenyl)methyl]triphenylphosphonium bromide (0.0.1 mol) in toluene (20ml), a solution of sodium ethoxide (0.01 moles of sodium in 15 ml of absolute ethanol) was added dropwise at room temperature, while stirring. After 10 min ethyl4-bromoacetylbenzoate (0.01 mol) was added, the mixture was stirred at room temperature for 50 min and at 1OO°C for 30 min, while a solution of sodium ethoxide (0.01 moles of sodium in 15ml of absolute ethanol) was added. The suspension was stirred all night at room temperature, filtered and the filtrate evaporated to give an oil. Ethanol was added, the precipitate was filtered, washed with ethanol, and crystallized. More product could be obtained by evaporation of ethanol and purification by column chromatography on silica gel, eluting with ethyl acetate/petroleum ether 1 :7 (Table 2) .
Hydrolysis to acids XIII, XlV, XIX, and XX
The ester IX, X, XV, or XVI (0.01 mol) was dissolved in ethanol (200ml) and 20% NaOH solution (200ml) was added. The mixture was refluxed for 1h, concentrated under reduced pressure, and extracted with ethyl acetate. The aqueous layer was acidified with 6N HCI and extracted again with ethyl acetate. The second organic extract was dried (Na2S04) and evaporated under reduced pressure, the crude acid was purified by crystallization (Tables2 and 3).
Reduction to isoflavans X and XIV
A solution of the ester IX or of the acid XIII (0.005 mol) in ethanol (200ml) was hydrogenated for 5h at 60 psi over 5% Pd/C (150mg). After filtration of the catalyst and evaporation of the solvent, the crude product was crystallized ( Table 3) .
Synthesis of oxazolines XI, XII and XVII from corresponding esters (IX, X and Xt-?
A solution of the ester IX, X, or XV (0.01 mol) and ethanolamine (0.02 mol) was heated at 135°C for 2 h. After cooling, the mixture was treated dropwise, in ice bath, with 6N HCI (10mI). The precipitate was collected by filtration, washed with water and dried to give the hydroxyethyl amide. Thionyl chloride (0.02 mol) was added dropwise with stirring, to a suspension of the amide in ethyl acetate (25ml). After 3 h at room temperature while stirring, the oxazoline hydrochloride was collected by filtration and washed with ethyl acetate. The hydrochloride was suspended in water, the suspension was alkalified with 2N NaOH and filtered. The free base was washed with water and crystallized (Tables 2  and 3 ).
Reduction to isoflavans XVI and XVIII
A solution of the proper isoflavene (XV or XVII) (0.001 mol) in ethanol (150ml) was hydrogenated at room temperatura.over 10% Pd/C (100mg), until absorbtion of the theoretical hydrogen amount. After filtration of the catalyst and evaporation of the solvent,the crude compound was chromatographed on silica gel, eluting with ethyl acetate/petroleum ether (1 : 20) or ethyl acetate, respectively. The residue of the appropriate fractions was crystallized (Table 3 ).
Materials and Experimental procedures: Virology

Cells and virus
The Ohio HeLa cell line was routinely grown in Eagle's minimum essential medium supplemented with 10% fetal calf serum (growth medium).
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Rhinovirus type 1B was grown in HeLa cells. The procedures for cell cultures and virus production were as described elsewhere .
Compound toxicity
Compounds were dissolved in ethanol (1 mg ml-1 or 0.1 mg rnl") and diluted at suitable concentrations in tissue culture medium.
The effect of compounds on Ohio HeLa cells was assessed in two ways: (a)cytopathic effect (CPE) in drug-exposed uninfected cells, and (b) inhibition of cell growth. Cell suspensions (1 x 10 4 cells per well) were seeded in 96-well tissue culture plates in growth medium containing serial two-fold dilutions of compounds. Four wells were utilized for each drug concentration. Cells were inspected daily under light microscopy to detect changes in cell morphology such as swelling, granularity, rounding, and floating. Three days after the addition of drugs, supernatant fluids were discarded, the adherent monolayers rinsed twice with phosphate-buffered saline (PBS)pH 7.4, and the number of cells of three wells was counted after trypsinization. The mean value was calculated. The remaining well was used to assess cell viability by neutral red uptake. The 50% toxic concentration (TC so ) was the dose of drug reducing cell proliferation by 50% of the control and was calculated by plotting the per cent reduction of cell number in drug-exposed cultures in function of drug concentration.
Viral cytopathic effect
To evaluate viral CPE, confluent monolayers of HeLa cells in 24-well plates were infected (1 h at 33°C) with HRV 1B at a multiplicity of 0.5 plaque forming units (PFU) per cell in the presence of serial five-fold dilutions of the compounds. Each concentration was tested in duplicate. After adsorption, the monolayers were washed once with PBS and added with medium (plus 2% fetal calf serum) containing the test compound at the same concentration as during the virus adsorption period. Plates were incubated at 33°C. They were checked by light microscopy and the results recorded usually after 2 days, when untreated infected controls showed a complete destruction of the cell layer. Viral CPE was graded on a progressive scale of 0 (normal cells) to 4 (100% CPE).
The MIC so was taken as the lowest concentration of compound that protected 50% of the cells from CPE; it was calculated by plotting the logarithm of drug concentration vs. the per cent reduction of CPE.
Plaque assay
The plaque assay technique was essentially that of Fiala and Kenny (1966) .Briefly, confluent rnonolayers of HeLa cells in 6-well plates were infected with a virus suspension producing about 100 plaques per well, in the presence or absence of five-fold dilutions of drugs. After incubation for 1h at 33°C, the cells were washed twice with PBS to remove unadsorbed virus and the monolayers were overlayed with medium with or without the corresponding concentrations of compounds. Plaques were counted after 72 h of incubation at 33°C. Three wells were utilized for each drug eoncentration and the mean value of plaque number was calculated. The IC so was the concentration of drug reducing the plaque number by 50% of the control. It was calculated by plotting the percentage of plaque reduction with respect to the control plaque count vs. the logarithm of compound dose to yield a dose/response line.
